Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell-Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 794-804

  Toor, Amir A ^a   Sabo, Roy T ^b   Chung, Harold M ^a   Roberts, Catherine ^a   Manjili, Rose H ^a   Song, Shiyu ^b   Williams, David C ^b   Edmiston, Wendy ^a   Gatesman, Mandy L ^a   Edwards, Richard W ^a   Ferreira Gonzalez, Andrea ^b   Clark, William B ^a   Neale, Michael C ^b,c   McCarty, John M ^a   Manjili, Masoud H ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absolute T cell count; Antithymocyte globulin; Graft versus host disease; Mixed chimerism; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PROLYMPHOCYTIC LEUKEMIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; RELAPSE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANIMALS; ANTIGENS, CD3; ANTILYMPHOCYTE SERUM; CHIMERISM; COHORT STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MIDDLE AGED; RABBITS; RECURRENCE; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84859877002     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.011     Document Type: Article

References (39)

1. Dey B.R., McAfee S., Sackstein R., et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol. Blood Marrow Transplant 2001, 7:604-612.
2. Remberger M., Storer B., Ringden O., et al. Association between pretransplant thymoglobulin and reduced nonrelapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002, 29:391-397.
3. Toor A., Rodriguez T., Bauml M., et al. Feasibility of conditioning with thymoglobulin and reduced-intensity TBI to reduce acute GVHD in recipients of allogeneic SCT. Bone Marrow Transplant 2008, 42:723-731.
4. Rodriguez-Luaces M., Ferra C., Martin-Henao G., et al. Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cell add-back. Eur J Haematol 2004, 73:162-168.
5. Juliusson G., Theorin N., Karlsson K., et al. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006, 37:503-510.
6. Russell J.A., Turner A.R., Larratt L., et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched-pair analysis. Biol Blood Marrow Transplant 2007, 13:299-306.
7. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched-pair analysis. Bone Marrow Transplant 2002, 30:681-686.
8. Portier D.A., Roberts C.H., Fletcher D.R., et al. Use of rabibit antithymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provided comparable dose dependant outcomes to matched related donor recipients. (Abstract) Biol Blood Marrow Transplant 2011, 17:S303.
9. Alyea E.P., Weller E., Fisher D.C., et al. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol. Blood Marrow Transplant 2002, 8:601-607.
10. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009, 50:1809-1817.
11. Saito B., Fukuda T., Yokoyama H., et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol. Blood Marrow Transplant 2008, 14:1148-1155.
12. Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003, 9:320-329.
13. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004, 104:2254-2262.
14. Bader P., Kreyenberg H., Hoelle W., et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem cell transplantation: possible role for preemptive immunotherapy?. J Clin Oncol 2004, 22:1696-1705.
15. Bader P., Kreyenberg H., Hoelle W., et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where preemptive immunotherapy may be effective. Bone Marrow Transplant 2004, 33:815-821.
16. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions: the long and winding road. How should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
17. Norlin A.C., Remberger M. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2011, 86:57-66.
18. Meyer R.G., Britten C.M., Wehler D., et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007, 109:374-382.
19. Meyer R.G., Wagner E.M., Konur A., et al. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation. Bone Marrow Transplant 2010, 45:668-674.
20. + count reconstitution is associated with survival. Bone Marrow Transplant 2007, 39:269-278.
21. Parkman R., Cohen G., Carter S.L., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:919-927.
22. Tomita Y., Sachs D.H., Khan A., et al. Additional monoclonal antibody (mAb) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3-Gy whole body irradiation. Transplantation 1996, 61:469-477.
23. Nikolic B., Zhao G., Swenson K., et al. A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT. Blood 2000, 96:1166-1172.
24. Dey B.R., McAfee S., Colby C., et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005, 128:351-359.
25. Spiegelhalter D.J., Abrams K.R., Myles J.P. Bayesian Approaches to Clinical Trials and Health Care Evaluation 2004, Wiley, West Sussex, UK.
26. Lawler M., McCann S.R., Marsh J.C., et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol 2009, 144:933-945.
27. Shaw B.E., Byrne J.L., Das-Gupta E., et al. The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. Biol Blood Marrow Transplant 2007, 13:550-559.
28. Saito A.M., Kami M., Mori S., et al. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 2007, 82:873-880.
29. Hardy N.M., Hakim F., Steinberg S.M., et al. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1022-1030.
30. Petersen S.L., Madsen H.O., Ryder L.P., et al. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day +14 as a predictor of acute graft-versus-host disease. Biol Blood Marrow Transplant 2004, 10:337-346.
31. Craddock C., Nagra S., Peniket A., et al. Factors predicting long-term survival after T-cell-depleted reduced-intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010, 95:989-995.
32. Zeiser R., Spyridonidis A., Wasch R., et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005, 19:814-821.
33. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
34. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996, 334:281-285.
35. Spellman S., Warden M.B., Haagenson M., et al. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2009, 15:856-863.
36. Levenga H., Woestenenk R., Schattenberg A.V., et al. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. Bone Marrow Transplant 2007, 40:585-592.
37. Koenecke C., Shaffer J., Alexander S.I., et al. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003, 31:911-923.
38. Sobecks R.M., Ball E.J., Askar M., et al. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:709-714.
39. Carlin B.P., Louis T.A. Bayes and Empirical Bayes Methods for Data Analysis 2000, Chapman & Hall/CRC, New York. 2nd ed.